IDH2 and astrocytoma (excluding glioblastoma): Within the WHO 2021 framework, histopathological grading adheres to the principles set by the WHO 2016 criteria, with the presence of necrosis and/or microvascular proliferation indicative of a grade 4 tumor, specifically classified as astrocytoma IDH mutant CNS WHO grade 4.